Acquisition Synergy Recent acquisition by Miraca Life Sciences creates strategic network integration, enabling cross-sell opportunities across MLS client accounts and the chance to position PLUS Diagnostics’ cytology, histology and molecular pathology services within a broader enterprise footprint.

MLS Network Access With MLS backing, PLUS gains broader access to hospitals and specialty clinics, accelerating multi-site contracts and enabling the MLS client base to tap PLUS’s subspecialties in GU, GI, dermatopathology, hematopathology, breast and oral and maxillofacial pathology.

Subspecialty Focus CAP accreditation combined with CLIA certification, and a diverse subspecialty portfolio, positions PLUS as a differentiated partner for tertiary centers seeking precise diagnostics and streamlined pathology workflows; ideal for academic medical centers and cancer centers.

Molecular Expansion Molecular pathology offerings align with ongoing precision medicine initiatives, creating opportunities to bundle cytology, histology and molecular testing within the MLS ecosystem and deliver scalable, end-to-end pathology solutions.

Quality Advantage Quality credentials and a mid-sized operating profile make PLUS an attractive long term partner for mid-to-large health systems; leverage CAP and CLIA distinctions to win enterprise RFPs and build durable relationships within the Miraca network.